Loading…
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients....
Saved in:
| Published in: | British journal of cancer 1995-05, Vol.71 (5), p.1029-1032 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c502t-54e2c81e8be67b13ee3c4fb88280a89a4674aa450e226d194c49e3372ad1e4013 |
|---|---|
| cites | |
| container_end_page | 1032 |
| container_issue | 5 |
| container_start_page | 1029 |
| container_title | British journal of cancer |
| container_volume | 71 |
| creator | Hietanen, P Blomqvist, C Wasenius, V-M Niskanen, E Franssila, K Nordling, S |
| description | The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared. |
| doi_str_mv | 10.1038/bjc.1995.198 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16878533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-54e2c81e8be67b13ee3c4fb88280a89a4674aa450e226d194c49e3372ad1e4013</originalsourceid><addsrcrecordid>eNp1kctv1DAQxi0EKtuFG1ckHxAnUvzIw7mAqrY8pAoOwNmaOLNdrxI72E6l_e9xtNEKDlzGHs_P34z9EfKKsyvOpHrfHcwVb9sqB_WEbHglRcGVaJ6SDWOsKVgr2HNyGeMhpy1TzQW5aBpZirbakMdbT2-_XdNp8LY_UnA9_VFMe4hIdwFMst5R6-gU7AjhSNM8-jnkFHtrEk17pAHj5F3mk6dmj6PPhwGm43JtxAQxQbKGdgHzlhpwBsPHF-TZDoaIL9d1S359uvt586W4__756831fWEqJlJRlSiM4qg6rJuOS0Rpyl2nlFAMVAtl3ZQAZcVQiLrnbWnKFqVsBPQcS8bllnw46U5zN2Jv0KUAg16foz1Y_W_F2b1-8I9asCxT11ng7SoQ_O8ZY9KjjQaHARz6OWpeq0ZVUmbw3Qk0wccYcHduwplefNLZJ734lIPK-Ou_BzvDqzG5_matQzQwZC-csfGMyYrJKs-4JcUJi7niHjDoQ_bH5S_9X1t64h2kOeBZL0MLsyB_ACmEtwA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16878533</pqid></control><display><type>article</type><title>Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?</title><source>PubMed Central</source><creator>Hietanen, P ; Blomqvist, C ; Wasenius, V-M ; Niskanen, E ; Franssila, K ; Nordling, S</creator><creatorcontrib>Hietanen, P ; Blomqvist, C ; Wasenius, V-M ; Niskanen, E ; Franssila, K ; Nordling, S</creatorcontrib><description>The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1995.198</identifier><identifier>PMID: 7734295</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Bone Neoplasms - secondary ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Cancer Research ; Chemotherapy ; Cyclophosphamide - administration & dosage ; DNA, Neoplasm - genetics ; Drug Administration Schedule ; Drug Resistance ; Epidemiology ; Epirubicin - administration & dosage ; experimental-oncology ; Female ; Fluorouracil - administration & dosage ; Humans ; Medical sciences ; Middle Aged ; Molecular Medicine ; Oncology ; Pharmacology. Drug treatments ; Ploidies ; Predictive Value of Tests ; S Phase - physiology ; Soft Tissue Neoplasms - secondary</subject><ispartof>British journal of cancer, 1995-05, Vol.71 (5), p.1029-1032</ispartof><rights>Cancer Research Campaign 1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-54e2c81e8be67b13ee3c4fb88280a89a4674aa450e226d194c49e3372ad1e4013</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033766/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033766/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3503520$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7734295$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hietanen, P</creatorcontrib><creatorcontrib>Blomqvist, C</creatorcontrib><creatorcontrib>Wasenius, V-M</creatorcontrib><creatorcontrib>Niskanen, E</creatorcontrib><creatorcontrib>Franssila, K</creatorcontrib><creatorcontrib>Nordling, S</creatorcontrib><title>Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone Neoplasms - secondary</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>DNA, Neoplasm - genetics</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Epirubicin - administration & dosage</subject><subject>experimental-oncology</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Ploidies</subject><subject>Predictive Value of Tests</subject><subject>S Phase - physiology</subject><subject>Soft Tissue Neoplasms - secondary</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNp1kctv1DAQxi0EKtuFG1ckHxAnUvzIw7mAqrY8pAoOwNmaOLNdrxI72E6l_e9xtNEKDlzGHs_P34z9EfKKsyvOpHrfHcwVb9sqB_WEbHglRcGVaJ6SDWOsKVgr2HNyGeMhpy1TzQW5aBpZirbakMdbT2-_XdNp8LY_UnA9_VFMe4hIdwFMst5R6-gU7AjhSNM8-jnkFHtrEk17pAHj5F3mk6dmj6PPhwGm43JtxAQxQbKGdgHzlhpwBsPHF-TZDoaIL9d1S359uvt586W4__756831fWEqJlJRlSiM4qg6rJuOS0Rpyl2nlFAMVAtl3ZQAZcVQiLrnbWnKFqVsBPQcS8bllnw46U5zN2Jv0KUAg16foz1Y_W_F2b1-8I9asCxT11ng7SoQ_O8ZY9KjjQaHARz6OWpeq0ZVUmbw3Qk0wccYcHduwplefNLZJ734lIPK-Ou_BzvDqzG5_matQzQwZC-csfGMyYrJKs-4JcUJi7niHjDoQ_bH5S_9X1t64h2kOeBZL0MLsyB_ACmEtwA</recordid><startdate>19950501</startdate><enddate>19950501</enddate><creator>Hietanen, P</creator><creator>Blomqvist, C</creator><creator>Wasenius, V-M</creator><creator>Niskanen, E</creator><creator>Franssila, K</creator><creator>Nordling, S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>5PM</scope></search><sort><creationdate>19950501</creationdate><title>Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?</title><author>Hietanen, P ; Blomqvist, C ; Wasenius, V-M ; Niskanen, E ; Franssila, K ; Nordling, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-54e2c81e8be67b13ee3c4fb88280a89a4674aa450e226d194c49e3372ad1e4013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone Neoplasms - secondary</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>DNA, Neoplasm - genetics</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Epirubicin - administration & dosage</topic><topic>experimental-oncology</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Ploidies</topic><topic>Predictive Value of Tests</topic><topic>S Phase - physiology</topic><topic>Soft Tissue Neoplasms - secondary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hietanen, P</creatorcontrib><creatorcontrib>Blomqvist, C</creatorcontrib><creatorcontrib>Wasenius, V-M</creatorcontrib><creatorcontrib>Niskanen, E</creatorcontrib><creatorcontrib>Franssila, K</creatorcontrib><creatorcontrib>Nordling, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hietanen, P</au><au>Blomqvist, C</au><au>Wasenius, V-M</au><au>Niskanen, E</au><au>Franssila, K</au><au>Nordling, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1995-05-01</date><risdate>1995</risdate><volume>71</volume><issue>5</issue><spage>1029</spage><epage>1032</epage><pages>1029-1032</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>7734295</pmid><doi>10.1038/bjc.1995.198</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1995-05, Vol.71 (5), p.1029-1032 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033766 |
| source | PubMed Central |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Bone Neoplasms - secondary Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Research Chemotherapy Cyclophosphamide - administration & dosage DNA, Neoplasm - genetics Drug Administration Schedule Drug Resistance Epidemiology Epirubicin - administration & dosage experimental-oncology Female Fluorouracil - administration & dosage Humans Medical sciences Middle Aged Molecular Medicine Oncology Pharmacology. Drug treatments Ploidies Predictive Value of Tests S Phase - physiology Soft Tissue Neoplasms - secondary |
| title | Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A48%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20DNA%20ploidy%20and%20S-phase%20fraction%20in%20primary%20tumour%20predict%20the%20response%20to%20chemotherapy%20in%20metastatic%20breast%20cancer?&rft.jtitle=British%20journal%20of%20cancer&rft.au=Hietanen,%20P&rft.date=1995-05-01&rft.volume=71&rft.issue=5&rft.spage=1029&rft.epage=1032&rft.pages=1029-1032&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1995.198&rft_dat=%3Cproquest_pubme%3E16878533%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c502t-54e2c81e8be67b13ee3c4fb88280a89a4674aa450e226d194c49e3372ad1e4013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16878533&rft_id=info:pmid/7734295&rfr_iscdi=true |